This segment focuses on the research, development, and clinical trials of gene therapies for inherited retinal diseases (IRDs), such as retinitis pigmentosa and Leber congenital amaurosis. Ocugen utilizes its proprietary modifier gene therapy platform, including OCU400, to restore retinal integrity and function. The segment involves preclinical studies, Phase 1/2 and Phase 2/3 clinical trials, and regulatory submissions. The goal is to provide effective treatments for patients suffering from IRDs, improving their vision and quality of life. This segment's market positioning is based on its innovative approach to treating IRDs, with potential for significant growth as clinical trials progress and regulatory approvals are obtained. Partnerships with CanSino Biologics Inc. for co-development and manufacturing are crucial for this segment's success.

This segment is dedicated to developing gene therapies for dry AMD, a leading cause of vision loss in older adults. The primary focus is on OCU410, a gene therapy candidate designed to address the underlying causes of dry AMD. Research and development activities include preclinical studies, clinical trials, and manufacturing processes. The segment aims to provide a treatment option for patients with dry AMD, potentially slowing or reversing vision loss. Market positioning relies on the unmet medical need for effective dry AMD treatments. The segment's future opportunities include expanding clinical trials, seeking regulatory approvals, and establishing partnerships for commercialization. The segment's success depends on the clinical trial results and regulatory approvals.

This segment focuses on the preclinical development of OCU200, a novel fusion protein, for the treatment of diabetic macular edema (DME), diabetic retinopathy, and wet AMD. Research and development activities include preclinical studies, formulation development, and manufacturing. The segment aims to address the growing prevalence of diabetic eye diseases and wet AMD, providing new treatment options for patients. Market positioning is based on the potential to address significant unmet medical needs in the diabetic eye disease and wet AMD markets. Future opportunities include advancing OCU200 through clinical trials and seeking regulatory approvals. The segment's success depends on the preclinical data and the ability to secure funding for clinical trials.